Economic costs of benign prostatic hyperplasia in the private sector
Economic costs of benign prostatic hyperplasia in the private sector
复制标题
DOI：
10.1097/01.ju.0000152318.79184.6f
复制
发表时间：
2005-04-01
影响因子：
6.6
通讯作者：
Joyce, G
中科院分区：
文献类型：
--
作者：
Saigal, CS;Joyce, G
目的：几项研究记录了良性前列腺增生（BPH）对工作的老年男性的影响。与BPH治疗相关的直接医疗费用主要由雇员通过更高的保险费承担。然而，与工作损失有关的间接费用主要由雇主承担。在这项研究中，我们使用的索赔数据和缺席记录从大雇主估计与BPH在工作年龄museum.Materials和方法相关的费用：我们使用了2个数据源，以检查与BPH在私人保险，nonelderly人口的直接和间接费用。使用多变量回归模型预测有和没有BPH医疗索赔的人的支出，控制相关协变量。工作损失的数据与医疗索赔估计工作损失相关的治疗BPH.Results：平均每年的支出为4,193美元的男性没有医疗索赔BPH。相比之下，患有BPH的男性的年支出为5，729美元。因此，与BPH诊断相关的增量成本为每年1，536美元。总体而言，平均员工的条件错过了7.3小时的工作，每年与BPH约10%的报告一些工作损失有关的医疗保健遇到BPH.Conclusions：治疗BPH的男性放置一个显着的负担，员工和他们的雇主通过直接的医疗费用，以及通过失去工作时间。私营部门与前列腺增生治疗有关的直接和间接费用估计为39亿美元。
Purpose: Several studies document the impact of benign prostatic hyperplasia (BPH) in working, aged men. Direct medical costs related to BPH treatment are largely borne by employees through higher premiums. However, indirect costs related to lost work are primarily borne by the employer. In this study we used claims data and absentee records from large employers to estimate the costs associated with BPH in working age males.Materials and Methods: We used 2 data sources to examine direct and indirect costs associated with BPH in a privately insured, nonelderly population. Multivariate regression models were used to predict spending for persons with and without a medical claim for BPH, controlling for relevant covariates. Data on work loss were linked to medical claims to estimate work loss related to treatment for BPH.Results: Mean annual expenditures were $4,193 for men without a medical claim for BPH. In contrast, annual spending was $5,729 for men with a claim for BPH. Thus, the incremental cost associated with a diagnosis of BPH was $1,536 yearly. Overall the average employee with the condition missed 7.3 hours of work yearly related to BPH with approximately 10% reporting some work loss related to a health care encounter for BPH.Conclusions: Treatment of men with BPH places a significant burden on employees and their employers through direct medical costs as well as through lost work time. Direct and indirect costs to the private sector related to BPH treatment are estimated to be $3.9 billion.